MediciNova, Inc. (MNOV) Social Stream
Medicinova Inc (MNOV) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering MNOV.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 46 weeks, MNOV's average price target has gone down $2.5.
MNOV reports an average of 305.82% for its upside potential over the past 43 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
MNOV Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 31 days, MNOV's average broker recommendation rating improved by 0.67.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MNOV as an investment opportunity.
- In terms of how Medicinova Inc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 195.59% of that group.
- Medicinova Inc's variance in analysts' estimates is lower than -89.43% of all US stocks.
- Medicinova Inc's number of analysts covering the stock is greater than 27.78% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Healthcare stocks, Medicinova Inc's average analyst price target is greater than 54.72% of them.
What is the outlook for MNOV? Use POWR Ratings for clearer insight into price direction.